Lifecycle Continuity Through Regulatory Compliance: A Comparative Evaluation of Post-Approval Change Strategies for APIs and Drug Products Under the Regulatory Frameworks of Saudi Arabia, the United States, Australia, and Eurasia
Abstract
The paper presents a parallel assessment of after-clearance change demands for drug substances between the regulatory structures of Saudi Arabia, US, Australia, and the Eurasian Economic Union. The regulatory structures that steer these changes in each area are fundamental for the upkeep of drug safety, usefulness, and standards as healthcare advances. The research strategy calls for a careful study of relevant standards, rules, and case assessments from all named realms. Key aspects such as the nature of amendments, data demands, clearance pathways, and treatment schedules are analyzed to understand the challenges of regulatory adherence. Added to that, the effect of these demands on market ventures, advancement, and access to treatments has been evaluated.
Conclusion: In conclusion, The Review also explain that this comparative analysis demonstrates that while Saudi Arabia, US, FDA, Australia, and Eurasian Economic Union regulations on API and drug product post-approval change management are all risk-based and critical to continued safety, efficacy, and quality, these regulations also vary with respect to classification, data, and timelines.
Downloads
References
https://jpionline.org/storage/2023/05/IntJPharm-Investigation-11-4-349.pdf.
2. U.S. Food and Drug Administration. Changes to an approved NDA or ANDA. Silver Spring (MD): FDA; 2004 [Internet]. U.S: USFDA; 30 Apr 2022 [cited 2025 Aug 22]. Available from:
https://www.fda.gov/files/drugs/published/Changes-to-an-Approved-NDA-or-ANDA.pdf.
3. Variations to prescription medicines – excluding variations requiring evaluation of clinical or bioequivalence data. Appendix 1: Variation types – chemical entities. Version 3.1; [Internet].Australia:TGA Jan 2020 [cited on 2025 September 03]. Available from:
https://www.tga.gov.au/sites/default/files/2024-10/variations-prescription-medicines-excluding-variations-requiring-evaluation-c.pdf.
4. Navale SA, Basarkar GD. Overview of Drug Approval Process and Post Approval Changes in Europe. Int J Drug Reg Affairs [Internet]. 2023 Dec.15 [cited 2025 Sep.15];11(4):1-15. Available from:
https://www.ijdra.com/index.php/journal/article/view/627
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
